bamlanivimab: Clinical Trials

5 trials of bamlanivimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5
Phase 22Completed 2

Follow bamlanivimab: new trials by email Literature Review of bamlanivimab trials Research Report on bamlanivimab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ACTIV-2: A Study for Outpatients With COVID-19
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19
Phase 2 / Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)40442020-08-192024-08-02
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
LY3819253, Placebo, Remdesivir - COVID-19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3142020-08-052023-12-27
ACTIV-3: Therapeutics for Inpatients With COVID-19
LY3819253, Placebo, Remdesivir - Covid19
Phase 3CompletedNational Institute of Allergy and Infectious Diseases (NIAID)27532020-08-042023-08-25
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Bamlanivimab, Placebo, Etesevimab - COVID-19, SARS-CoV2
Phase 3CompletedEli Lilly and Company11802020-08-022022-02-04
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
LY3819253, LY3832479, LY3853113 - COVID-19
Phase 2 / Phase 3CompletedEli Lilly and Company33072020-06-172024-04-11

Conditions studied

COVID-19 (5)  ·  Coronaviridae Infections (3)  ·  Coronavirus Infections (3)  ·  Nidovirales Infections (3)  ·  RNA Virus Infections (3)  ·  Severe Acute Respiratory Syndrome (3)  ·  Virus Diseases (3)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Eli Lilly and Company (2)

Countries

United States (5)  ·  Denmark (2)  ·  Singapore (2)  ·  Spain (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Greece (1)  ·  Guatemala (1)  ·  Mexico (1)  ·  Nigeria (1)  ·  Philippines (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  South Africa (1)

Top investigators

David Smith, MD, MAS (1)  ·  James Neaton, Prof. (1)  ·  Jens Lundgren, Prof. (1)  ·  Prof. James Neaton (1)  ·  Prof. Jens Lundgren (1)

Results publications

PMID 34473343, PMID 35713300, PMID 33356051, PMID 34374951, PMID 33113295, PMID 33475701, PMID 34081073, PMID 34260849, PMID 34346827, PMID 34718468, PMID 34928698, PMID 34953520, PMID 34981077, PMID 35298440, PMID 35493124, PMID 35793677, PMID 35797235, PMID 35817072, PMID 35939810, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37329415, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 37948759, PMID 39018444, PMID 39028902, PMID 39230829, PMID 39922466, PMID 40262279, PMID 42148571